CKD Bio Corp. (KRX:063160)

South Korea · Delayed Price · Currency is KRW

19,440

-70 (-0.36%)

At close: Mar 13, 2026

Revenue by Segment

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2012	FY 2011	FY 2010	FY 2009	FY 2008
Period Ending	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '12 Dec 31, 2012	Dec '11 Dec 31, 2011	Dec '10 Dec 31, 2010	Dec '09 Dec 31, 2009	Dec '08 Dec 31, 2008
Raw Drug Product Division	125.09B	108.21B	109.15B	-	-
Raw Drug Product Division Growth	15.60%	-0.87%	-	-	-
Probiotics Division	24.98B	34.03B	15.45B	-	-
Probiotics Division Growth	-26.59%	120.32%	-	-	-
Botulinum Toxin Division	5.97B	-	-	-	-
Medicine Business	-	-	-	137.18B	124.51B
Medicine Business Growth	-	-	-	10.18%	9.45%
Total	156.04B	142.24B	124.60B	137.18B	124.51B
Total Growth	9.70%	14.16%	-9.17%	10.18%	9.45%

Revenue by Geography

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2012	FY 2011	FY 2010	FY 2009	FY 2008
Period Ending	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '12 Dec 31, 2012	Dec '11 Dec 31, 2011	Dec '10 Dec 31, 2010	Dec '09 Dec 31, 2009	Dec '08 Dec 31, 2008
South Korea	156.04B	142.24B	124.60B	137.18B	124.51B
South Korea Growth	9.70%	14.16%	-9.17%	10.18%	9.45%
Total	156.04B	142.24B	124.60B	137.18B	124.51B
Total Growth	9.70%	14.16%	-9.17%	10.18%	9.45%

Source: S&P Global Market Intelligence.